Find Clinical Trial

Phase I dose escalation study of oral administration of Pan-Histone Deacetylase (HDAC) inhibitor S 78454 given in combination with a fixed dose infusion of cisplatin in patients with advanced non-keratinising nasopharyngeal carcinoma.


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

Active substance/
Medical device

ABEXINOSTAT, S078454

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS078454
Protocol CodeCL1-78454-009
ISRCTN CodeISRCTN96922360


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility